AI assistant
MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2023
Jan 19, 2023
30608_dirs_2023-01-18_da1b850b-6538-44a5-bd4f-d3967e8f12d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2023-01-16
Reporting Person: Taub Rebecca (Director, Pres., R&D, and CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-16 | Common Stock | A | 20001 | $0.00 | Acquired | 20001 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 434758 | Direct |
| Common Stock | 655540 | Indirect |
Footnotes
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
F2: The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.